
    
      A single-centre, randomised, double-blind, placebo-controlled, dose-ascending, 3-cohort
      parallel-group study to evaluate the safety, tolerability, pharmacodynamics and
      pharmacokinetics of GSK573719 administered as single doses (750µg and 1000µg) and repeat
      doses over 14 days (250µg-1000µg once-daily) of GSK573719 in healthy male and female subjects
    
  